Cargando…
Update on hidradenitis suppurativa: connecting the tracts
Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by recurrent abscesses, sinus tract formation, and scarring. Prevalence estimates range from 0.053% to 4.1%, although HS is likely an underdiagnosed disease. Although the first reports of HS date back to the mid-19th century,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278191/ https://www.ncbi.nlm.nih.gov/pubmed/25580266 http://dx.doi.org/10.12703/P6-112 |
_version_ | 1782350481924816896 |
---|---|
author | Gill, Liza Williams, Melissa Hamzavi, Iltefat |
author_facet | Gill, Liza Williams, Melissa Hamzavi, Iltefat |
author_sort | Gill, Liza |
collection | PubMed |
description | Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by recurrent abscesses, sinus tract formation, and scarring. Prevalence estimates range from 0.053% to 4.1%, although HS is likely an underdiagnosed disease. Although the first reports of HS date back to the mid-19th century, the disease continues to plague patients and physicians desperate for a definitive treatment. Advances in the understanding of the disease process include the possibility of a defective basement membrane at the sebofollicular junction of the folliculopilosebaceous unit (FPSU; that is, where the sebaceous gland empties into the hair follicle) as an initiating event followed by secondary bacterial colonization. New evidence suggests that bacteria living in a community, known as a biofilm, rather than single planktonic bacteria in HS lesions may explain why HS can be resistant to current antibiotic treatment regimens. Available treatment options have expanded to include triple-antibiotic therapy, tumor necrosis factor (TNF-α) and interleukin-1 (IL-1) inhibitors (biologics), laser therapy, and surgical excision, including the skin tissue-sparing excision with electrosurgical peeling procedure. Despite the array of treatments available, many patients continue to struggle with the embarrassment, pain, odor, and frustration that accompany this often isolating disease. Physicians should address comorbidities in HS, including the psychosocial issues patients with HS frequently encounter. Patients can be directed to HS support groups, where they can openly discuss their frustrations, share their experiences in dealing with HS, and band together to advocate for themselves. HS is misunderstood by both patients and physicians, often resulting in a delay in clinical presentation and diagnosis. Patients and physicians across multiple specialties must work together to expand awareness of and interest in HS, so that one day, individuals with HS can be freed from this crippling disease. |
format | Online Article Text |
id | pubmed-4278191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Faculty of 1000 Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42781912015-01-09 Update on hidradenitis suppurativa: connecting the tracts Gill, Liza Williams, Melissa Hamzavi, Iltefat F1000Prime Rep Review Article Hidradenitis suppurativa (HS) is a debilitating skin disease characterized by recurrent abscesses, sinus tract formation, and scarring. Prevalence estimates range from 0.053% to 4.1%, although HS is likely an underdiagnosed disease. Although the first reports of HS date back to the mid-19th century, the disease continues to plague patients and physicians desperate for a definitive treatment. Advances in the understanding of the disease process include the possibility of a defective basement membrane at the sebofollicular junction of the folliculopilosebaceous unit (FPSU; that is, where the sebaceous gland empties into the hair follicle) as an initiating event followed by secondary bacterial colonization. New evidence suggests that bacteria living in a community, known as a biofilm, rather than single planktonic bacteria in HS lesions may explain why HS can be resistant to current antibiotic treatment regimens. Available treatment options have expanded to include triple-antibiotic therapy, tumor necrosis factor (TNF-α) and interleukin-1 (IL-1) inhibitors (biologics), laser therapy, and surgical excision, including the skin tissue-sparing excision with electrosurgical peeling procedure. Despite the array of treatments available, many patients continue to struggle with the embarrassment, pain, odor, and frustration that accompany this often isolating disease. Physicians should address comorbidities in HS, including the psychosocial issues patients with HS frequently encounter. Patients can be directed to HS support groups, where they can openly discuss their frustrations, share their experiences in dealing with HS, and band together to advocate for themselves. HS is misunderstood by both patients and physicians, often resulting in a delay in clinical presentation and diagnosis. Patients and physicians across multiple specialties must work together to expand awareness of and interest in HS, so that one day, individuals with HS can be freed from this crippling disease. Faculty of 1000 Ltd 2014-12-01 /pmc/articles/PMC4278191/ /pubmed/25580266 http://dx.doi.org/10.12703/P6-112 Text en © 2014 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Gill, Liza Williams, Melissa Hamzavi, Iltefat Update on hidradenitis suppurativa: connecting the tracts |
title | Update on hidradenitis suppurativa: connecting the tracts |
title_full | Update on hidradenitis suppurativa: connecting the tracts |
title_fullStr | Update on hidradenitis suppurativa: connecting the tracts |
title_full_unstemmed | Update on hidradenitis suppurativa: connecting the tracts |
title_short | Update on hidradenitis suppurativa: connecting the tracts |
title_sort | update on hidradenitis suppurativa: connecting the tracts |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278191/ https://www.ncbi.nlm.nih.gov/pubmed/25580266 http://dx.doi.org/10.12703/P6-112 |
work_keys_str_mv | AT gillliza updateonhidradenitissuppurativaconnectingthetracts AT williamsmelissa updateonhidradenitissuppurativaconnectingthetracts AT hamzaviiltefat updateonhidradenitissuppurativaconnectingthetracts |